FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to drugs and concerns a pharmaceutical combination containing the effective amounts of: (i) a compounds
, where Ln·R5 m, R1, R2, R3 and R4 have values specified in the formula and (ii) at least one additional therapeutic agent 2 chosen from a group consisting of nucleoside biphosphate reductase inhibitors chosen from cytarabine and pemetrexed, histone deacetylase inhibitors, irinotecan, docetaxel, cisplatin, taxotere, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-butene-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline or its pharmaceutically acceptable salt and 3-Z-[1-(4-(N-((4-methylpiperazine-1-yl)-methylcarbonyl)-N-methylamino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone for oncotherapy.
EFFECT: combination under the invention shows a synergetic effect in oncotherapy.
18 cl, 8 dwg, 1 tbl, 25 ex
